Center for Biomedical Research, Inc., Boise, ID 83706, USA.
Center for Biomedical Research, Inc., Boise, ID 83706, USA.
Biomed Pharmacother. 2022 Apr;148:112710. doi: 10.1016/j.biopha.2022.112710. Epub 2022 Feb 24.
Skin cancer is the most common cancer in the United States and among Caucasians worldwide, with more people diagnosed each year than all other cancers combined. Basal cell cancer is the most common form with an estimated 4.3 million cases diagnosed annually, and treatment costs estimated at $4.8 billion. The objective of this study was to compare efficacy of a topical solution consisting of 30% ascorbic acid in 95% dimethylsulfoxide with topical imiquimod in the treatment of basal cell carcinoma. Twenty-five patients with 29 biopsy confirmed basal cell carcinomas were randomly assigned to receive either the topically applied ascorbic acid treatment twice daily for 8 weeks or topical imiquimod, a standard and well characterized topical treatment. After 8 weeks, post-treatment biopsy of lesions showed complete resolution of 13/15 (86.7%) in the ascorbic acid group, while 8/14 (57.1%) lesions in the IMQ group were resolved (p < 0.05 Chi Square). Topical ascorbic acid was superior at 8 weeks, and non-inferior at 12 weeks to topical imiquimod in the treatment of low risk nodular and superficial lesions. In addition, ascorbic acid was associated with fewer adverse effects than imiquimod. 70% of patients in the imiquinod group showed residual hypopigmentation at 30mo follow up versus 0% in the ascorbate group.
皮肤癌是美国和全球白种人中最常见的癌症，每年被诊断出的病例比所有其他癌症加起来还要多。基底细胞癌是最常见的类型，每年估计有 430 万例，治疗费用估计为 48 亿美元。本研究的目的是比较 30%抗坏血酸在 95%二甲基亚砜中的局部溶液与局部咪喹莫特治疗基底细胞癌的疗效。25 例 29 例活检证实的基底细胞癌患者随机分为两组，一组接受每日两次局部涂抹抗坏血酸治疗 8 周，另一组接受局部涂抹咪喹莫特治疗，这是一种标准的、特征明确的局部治疗方法。8 周后，对病变进行治疗后活检显示，在抗坏血酸组中，13/15（86.7%）病变完全消退，而在咪喹莫特组中，8/14（57.1%）病变消退（p<0.05 卡方检验）。在治疗低风险结节性和浅表性病变方面，局部抗坏血酸在 8 周时效果优于咪喹莫特，在 12 周时非劣效于咪喹莫特。此外，抗坏血酸的不良反应比咪喹莫特少。在 30 个月的随访中，咪喹莫特组有 70%的患者出现残留色素减退，而抗坏血酸组则为 0%。
